Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
Sponsor: Nanjing IASO Biotechnology Co., Ltd.
Summary
This is a multicenter, open-label, single-arm, long-term follow-up clinical study. All patients who have received Equecabtagene Autoleucel Injection treatment will be enrolled.
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
1500
Start Date
2024-12-15
Completion Date
2043-12
Last Updated
2025-06-19
Healthy Volunteers
No
Conditions
Interventions
No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) )
This study is observational study and all participants will be obsreved with no intervention.
Locations (6)
Peking University First Hospital
Beijing, China
People's Hospital of Peking Universit
Beijing, China
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
Tianjin Medical University General Hospital
Tianjin, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University
Zhengzhou, China